Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

ClinicalTrials.gov ID: NCT03941964

Public ClinicalTrials.gov record NCT03941964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML who are ineligible for intensive chemotherapy.

Study identification

NCT ID
NCT03941964
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
60 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 14, 2019
Primary completion
Mar 13, 2022
Completion
Mar 13, 2022
Last update posted
Mar 19, 2023

2019 – 2022

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
15
Facility City State ZIP Site status
Arizona Oncology Associates, PC-HOPE /ID# 211509 Tempe Arizona 85284-1812
Colorado Blood Cancer Institute /ID# 212800 Denver Colorado 80218
Rocky Mountain Cancer Centers /ID# 211508 Lone Tree Colorado 80124
Fort Wayne Medical Oncology /ID# 223523 Fort Wayne Indiana 46804
Minnesota Oncology Hematology, PA /ID# 212837 Minneapolis Minnesota 55404
Oncology Hematology Care, Inc. /ID# 212779 Cincinnati Ohio 45236-2725
Willamette Valley Cancer Institute and Research Center /ID# 211504 Eugene Oregon 97401-6043
Charleston Oncology, P.A. /ID# 211471 Charleston South Carolina 29414-7710
Prisma Health Cancer Inst - Eastside /ID# 211466 Greenville South Carolina 29615
Tennessee Oncology - Chattanooga / McCallie /ID# 212717 Chattanooga Tennessee 37404-3230
Tennessee Oncology-Nashville Centennial /ID# 210944 Nashville Tennessee 37203-1632
Texas Oncology - Austin Midtown /ID# 212780 Austin Texas 78705
Texas Oncology - Medical City Dallas /ID# 211503 Dallas Texas 75230
Texas Transplant Institute /ID# 213311 San Antonio Texas 78229
Texas Oncology - San Antonio Medical Center /ID# 211510 San Antonio Texas 78240-5251
Texas Oncology - Northeast Texas /ID# 213908 Tyler Texas 75702

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03941964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2023 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03941964 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →